Abstract
Esophagogastric cancers (EG cancers) are associated with high mortality and poor treatment outcomes due to advanced disease at diagnosis. Reliable non-invasive biomarkers are lacking for detection and prognostication. The aim of this study was to assess the clinical utility of methylated BCAT1 and IKZF1 circulating tumour DNA (ctDNA) for detection and prognosis of EG cancers.
Original language | English |
---|---|
Pages (from-to) | 348 |
Number of pages | 2 |
Journal | Journal of Clinical Oncology |
Volume | 40 |
Issue number | 4 suppl |
DOIs | |
Publication status | Published - 1 Feb 2022 |
Event | 2022 ASCO Gastrointestinal Cancers Symposium - San Francisco, United States Duration: 20 Jan 2022 → 22 Jan 2022 |
Keywords
- BCAT1
- IKZF1
- esophagogastric cancers
- Diagnostic biomarkers
- Prognostic biomarkers
- tumor DNA